Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Summit Therapeutics plc : Holding(s) in Company

Summit Therapeutics plc
Posted on: 05 Apr 18

TR-1: S tandard form for notification of major holdings

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : SUMMIT THERAPEUTICS PLC
1b. Please indicate if the issuer is a non-UK issuer   (please mark with an "X" if appropriate)
Non-UK issuer 
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rightsX
An acquisition or disposal of financial instruments 
An event changing the breakdown of voting rightsX
Other (please specify) iii :  
3. Details of person subject to the notification obligation iv
NameCANACCORD GENUITY GROUP INC
City and country of registered office (if applicable)VANCOUVER, CANADA
4. Full name of shareholder(s) (if different from 3.) v
NameDISCRETIONARY CLIENTS
City and country of registered office (if applicable)As above
5. Date on which the threshold was crossed or reached vi : 29 MARCH 2018
6. Date on which issuer notified (DD/MM/YYYY): 02 JULY 2018
7. Total positions of person(s) subject to the notification obligation
 % of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B) Total number of voting rights of issuer vii
Resulting situation on the date on which threshold was crossed or reached6.7647 6.764781,901,173
Position of previous notification (if
applicable)
4.1548 4.1548 


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)
Number of voting rights ix % of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BN40HZ01N/A5,540,382N/A6.7647
     
     

SUBTOTAL 8. A 5,540,3826.7647
 

 
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument Expiration
date x
Exercise/
Conversion Period xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
     
     
     
   SUBTOTAL 8. B 1   
 

 
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument Expiration
date x
Exercise/
Conversion Period xi
Physical or cash
settlement xii
Number of voting rights % of voting rights
      
      
      
     SUBTOTAL 8.B.2   
 

  
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii  
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary)
X
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Canaccord Genuity Group Inc.6.7647 6.7647
Canaccord Genuity Wealth Group Holdings Limited6.7647 6.7647
Canaccord Genuity Wealth Group Holdings (Jersey) Limited6.7647 6.7647
Hargreave Hale Ltd6.7647 6.7647
 
10. In case of proxy voting, please identify:
Name of the proxy holder 
The number and % of voting rights held 
The date until which the voting rights will be held 
 
11. Additional information xvi
The change in the percentage of shares held is due entirely to participation in the placing by Summit Therapeutics plc, the shares from which were admitted to AIM on 29/03/2018.

Place of completion BLACKPOOL, ENGLAND
Date of completion 02 JULY 2018


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Summit Therapeutics plc via GlobeNewswire
HUG#2202743
GlobeNewswire
globenewswire.com

Last updated on: 03/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.